TheraCryf is a clinical stage therapeutics company developing a new generation of innovative therapeutics in oncology and behavioural brain disorders. TheraCryfs strategy is to generate compelling data sets with a goal of partnering its programmes with mid-size to large pharma. The Companys clinical asset is SFX-01, a patented sulforaphane-based medicine. Chronos neuropsychiatry assets use novel chemistry to address highly relevant targets in brain health and have composition of matter patent cover. The Group Company has the expertise to develop and commercialise the combined portfolio.
CEO: |
Huw Jones |
CFO: |
Toni Hänninen |
Interim Chairman: |
Susan (Sue) Foden |
Independent Non-Executive Director: |
Alan Barge |
Address: |
Liverpool Science Park Innovation Centre 2, 146 Brownlow Hill, Liverpool, Merseyside, United Kingdom |
Phone: |
|
Fax: |
|
Website: |
http://www.theracryf.com/ |
Email: |
|